249 related articles for article (PubMed ID: 10178653)
1. The role of cost-consequence analysis in healthcare decision-making.
Mauskopf JA; Paul JE; Grant DM; Stergachis A
Pharmacoeconomics; 1998 Mar; 13(3):277-88. PubMed ID: 10178653
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness league tables: valuable guidance for decision makers?
Mauskopf J; Rutten F; Schonfeld W
Pharmacoeconomics; 2003; 21(14):991-1000. PubMed ID: 13129413
[TBL] [Abstract][Full Text] [Related]
3. Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.
Franklin M; Lomas J; Richardson G
Pharmacoeconomics; 2020 Jul; 38(7):665-681. PubMed ID: 32291596
[TBL] [Abstract][Full Text] [Related]
4. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
5. Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?
Karnon J; Partington A
Pharmacoeconomics; 2015 Dec; 33(12):1281-8. PubMed ID: 26100285
[TBL] [Abstract][Full Text] [Related]
6. QALYs: are they helpful to decision makers?
McGregor M; Caro JJ
Pharmacoeconomics; 2006; 24(10):947-52. PubMed ID: 17002477
[TBL] [Abstract][Full Text] [Related]
7. Using cost-effectiveness analysis for formulary decision making: from theory into practice.
Detsky AS
Pharmacoeconomics; 1994 Oct; 6(4):281-8. PubMed ID: 10147465
[TBL] [Abstract][Full Text] [Related]
8. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
[TBL] [Abstract][Full Text] [Related]
9. Economic aspects of clinical decision making: applications in patient care.
Oster G
Am J Hosp Pharm; 1988 Mar; 45(3):543-7. PubMed ID: 3130753
[TBL] [Abstract][Full Text] [Related]
10. An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.
Franklin M; Lomas J; Walker S; Young T
Pharmacoeconomics; 2019 May; 37(5):631-643. PubMed ID: 30746613
[TBL] [Abstract][Full Text] [Related]
11. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
Danzon PM; Drummond MF; Towse A; Pauly MV
Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
[TBL] [Abstract][Full Text] [Related]
12. Health economics in drug development: efficient research to inform healthcare funding decisions.
Hall PS; McCabe C; Brown JM; Cameron DA
Eur J Cancer; 2010 Oct; 46(15):2674-80. PubMed ID: 20655197
[TBL] [Abstract][Full Text] [Related]
13. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
14. Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?
Davies LM; Fargher EA; Tricker K; Dawes P; Scott DL; Symmons D
Ann Rheum Dis; 2007 May; 66(5):658-63. PubMed ID: 17124249
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
16. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
17. Burden of Disease Study and Priority Setting in Korea: an Ethical Perspective.
Park SY; Kwon I; Oh IH
J Korean Med Sci; 2016 Nov; 31 Suppl 2(Suppl 2):S108-S113. PubMed ID: 27775247
[TBL] [Abstract][Full Text] [Related]
18. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals.
Koopmanschap MA; Stolk EA; Koolman X
Int J Technol Assess Health Care; 2010 Apr; 26(2):198-204. PubMed ID: 20392324
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
